Quarterly ResultMay 15, 2026, 04:09 PM
aTyr Pharma Q1 Net Loss $(10.8)M, EPS $(0.11)
AI Summary
aTyr Pharma reported a consolidated net loss of $(10.8) million, or $(0.11) per share, for the first quarter of 2026, an improvement from $(14.9) million, or $(0.17) per share, in the prior year period. This reduction was primarily driven by a significant decrease in research and development expenses. However, the company also announced the termination of its collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for efzofitimod in Japan, a partnership that had generated $20.0 million in milestone payments. Additionally, aTyr Pharma is facing ongoing securities class action litigation, with its CFO recently added as a defendant.
Key Highlights
- Net loss attributable to aTyr Pharma, Inc. decreased to $(10.8) million for Q1 2026 from $(14.9) million for Q1 2025.
- Net loss per share improved to $(0.11) for Q1 2026 from $(0.17) for Q1 2025.
- Research and development expenses decreased to $7.3 million in Q1 2026 from $11.8 million in Q1 2025.
- Cash, cash equivalents, restricted cash, and available-for-sale investments totaled $68.3 million as of March 31, 2026.
- The company believes existing liquidity is sufficient to meet material cash requirements for at least one year.
- The collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. was terminated on May 12, 2026.
- Ongoing securities class action litigation added the Chief Financial Officer as a defendant in an amended complaint.
- Did not utilize the Jefferies ATM Offering Program during Q1 2026.
Price Impact
More from ATYR